For patients with concurrent PredicinePLUSTM and Guardant360 testing (N = 14), high concordance was observed in orthogonal samples across representative genomic alterations (ESR1 92.9%, PIK3CA 100%, MYC copy number variations 71.4%) (Gerratana L, Zhang Z, Shah A, Davis A, Zhan Y, Qiang W, Finkelman B, Flaum L, Behdad A, Gradishar WJ et al: Analytical and clinical performance of a novel next generation sequencing-based (NGS) circulating tumor DNA (ctDNA) platform for the evaluation of samples from metastatic breast cancer (MBC). The gene discussed is ESR1; the disease is neoplasm.